Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Equity Average (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Equity Average data on record, last reported at -$99.1 million in Q4 2025.

  • For Q4 2025, Equity Average fell 168.45% year-over-year to -$99.1 million; the TTM value through Dec 2025 reached -$99.1 million, down 168.45%, while the annual FY2025 figure was -$77.0 million, 25.51% down from the prior year.
  • Equity Average reached -$99.1 million in Q4 2025 per FHTX's latest filing, down from -$83.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $135.7 million in Q1 2021 and bottomed at -$99.1 million in Q4 2025.
  • Average Equity Average over 5 years is -$2.6 million, with a median of -$29.1 million recorded in 2024.
  • Peak YoY movement for Equity Average: soared 1282.56% in 2021, then crashed 650.76% in 2023.
  • A 5-year view of Equity Average shows it stood at $88.9 million in 2021, then plummeted by 86.26% to $12.2 million in 2022, then plummeted by 650.76% to -$67.3 million in 2023, then soared by 45.15% to -$36.9 million in 2024, then plummeted by 168.45% to -$99.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$99.1 million in Q4 2025, -$83.2 million in Q3 2025, and -$69.2 million in Q2 2025.